Title |
Biomarkers for antitumor activity of bevacizumab in gastric cancer models
|
---|---|
Published in |
BMC Cancer, January 2012
|
DOI | 10.1186/1471-2407-12-37 |
Pubmed ID | |
Authors |
Yoriko Yamashita-Kashima, Kaori Fujimoto-Ouchi, Keigo Yorozu, Mitsue Kurasawa, Mieko Yanagisawa, Hideyuki Yasuno, Kazushige Mori |
Abstract |
Bevacizumab is a humanized monoclonal antibody to human vascular endothelial cell growth factor (VEGF) and has been used for many types of cancers such as colorectal cancer, non-small cell lung cancer, breast cancer, and glioblastoma. Bevacizumab might be effective against gastric cancer, because VEGF has been reported to be involved in the development of gastric cancer as well as other cancers. On the other hand, there are no established biomarkers to predict the bevacizumab efficacy in spite of clinical needs. Therefore, we tried to identify the predictive markers for efficacy of bevacizumab in gastric cancer patients by using bevacizumab-sensitive and insensitive tumor models. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Chile | 1 | 2% |
Spain | 1 | 2% |
France | 1 | 2% |
Unknown | 52 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 16 | 29% |
Student > Ph. D. Student | 12 | 22% |
Student > Postgraduate | 5 | 9% |
Student > Master | 4 | 7% |
Other | 3 | 5% |
Other | 6 | 11% |
Unknown | 9 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 20 | 36% |
Agricultural and Biological Sciences | 12 | 22% |
Biochemistry, Genetics and Molecular Biology | 6 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
Psychology | 2 | 4% |
Other | 5 | 9% |
Unknown | 8 | 15% |